Managing patients with small cell lung cancer:
efficacy and safety of tarlatamab for the treatment of previously treated ES-SCLC, with a focus on managing BiTE-specific adverse events.
INTRODUCTION
Small cell lung cancer (SCLC) is an aggressive malignancy that presents significant treatment challenges, particularly in the extensive-stage (ES) setting. For patients with relapsed or refractory disease, novel therapies like tarlatamab—a bispecific T-cell engager (BiTE)—offer promising efficacy but require careful management of unique adverse events.
In this insightful session, leading experts in thoracic oncology will discuss pivotal advances in the treatment of ES-SCLC, with a focus on the role of tarlatamab in previously treated patients. Drawing on key data from recent clinical trials and medical congresses, our panel will examine the drug’s efficacy, safety profile, and best practices for mitigating BiTE-related toxicities. Attendees will gain valuable insights into optimizing patient selection, monitoring, and adverse event management to improve outcomes in this high-need population.
BEGIN
THis Prgram is separated into 2 sections:
INTERACTIVE EXPLAINER VIDEO (IDEV)
Users will be able to review the phase 2 DeLLphi data for tarlatamab in previously treated ES-SCLC
Interactive ROUNDTABLE:
Lung cancer providers have limited experience using BiTE therapies and are therefore not accustomed to managing the unique AEs seen with this class. While most AEs are mild, a small percentage of patients will experience serious, potentially life-threatening CRS or ICANs.
Learning Goal
The primary objective is to educate HCPs on the efficacy and safety of tarlatamab for the treatment of previously treated ES-SCLC, with a focus on managing BiTE-specific adverse events.
Target Audience
This educational activity is designed for Canadian healthcare professionals (HCPs) involved in the care of adults with small cell lung cancer (SCLC), particularly those managing extensive-stage (ES) SCLC in the relapsed/refractory setting.
Relevant HCPs include:
- Medical Oncologists and Thoracic Oncologists
- Respiratory physicians and Respirologists
- Oncology nurses and advanced practice providers (e.g., nurse practitioners, physician assistants)
- Pharmacists specializing in oncology
- Allied healthcare professionals supporting SCLC patient care
Learning OBJECTIVES
- Describe the burden of SCLC, with Canada-specific data, if available
- Explain the mechanism of tarlatamab
- Provide practical guidance for recognizing and managing treatment-related AEs associated with tarlatamab
FACULTY
RANDEEP SANGHA
MD, FRCPC
Associate Professor
The University of Alberta and a Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta, Canada.
STEPHANIE SNOW
MD, FRCPC
Medical Oncologist, QEII Health Sciences Centre
Dalhousie University
President, Lung Cancer, Halifax, Canada
SHAQIL KASSAM
MD, MSc, FRCPC
Staff Medical Oncologist
Head of Clinical Research
Stronach Regional Cancer Centre
Newmarket, Ontario, Canada.
Disclosure STATEMENT
Funding Disclosure:
This independent medical education program is supported by Amgen Canada. Amgen Canada has provided funding for speaker honoraria and program administration.
Independence Statement:
The views and opinions expressed in this activity are solely those of the faculty and do not necessarily reflect those of Amgen Canada. The content is intended for educational purposes only and is not influenced by the supporter.
Intended Use:
This information is not a substitute for professional medical judgment. Healthcare providers must use their clinical expertise, along with approved product monographs, when making treatment decisions. Refer to the Canadian product labeling for full prescribing details, including indications, contraindications, warnings, and adverse events.
Disclaimer:
Case examples used in this activity are fictional. Any resemblance to real patients or clinical scenarios is unintentional.
Supported by
